SHORT REPORT

Prevalence of Human Immunodeficiency Virus and Opportunistic Infections Among Transgender Patients in the Clinical Setting: An All-Payer Electronic Health Record Database Study

Joshua D. Niforatos,¹ Jonathon W. Wanta,^{2,*} Emily Durbak,³ Jacqueline Cavendish,⁴ and Justin A. Yax^{4,5}

Abstract

We performed a cross-sectional analysis of the prevalence of HIV and opportunistic infections among transgender patients in clinical care. Of 10,160 transgender patients identified, 3.9% had a diagnosis of HIV, compared to 0.32% in the non-transgender cohort ($p < 0.0001$). Transgender patients experience the burden of all opportunistic infection compared to non-transgender patients in this analysis, although prevalence of pneumocystis pneumonia was not significant. This cohort-based, all-payer electronic health record study of HIV patients connected to care revealed that transgender patients have a higher prevalence of HIV infection and opportunistic infections compared to the non-transgender cohort.

Keywords: Explorys; HIV; opportunistic infection; transgender

Introduction

In the United States, ~1.4 million adults identify as transgender.^{1–3} Methods to estimate the prevalence of human immunodeficiency virus in this population rely on questions from survey studies.^{4–7} The reported population prevalence of HIV in these studies ranges from 1.4% among all transgender persons to 3.4% to 21% among transgender women.^{4,8} However, these data may underestimate the actual prevalence of HIV in this population. For example, in one study, almost half of all the survey respondents did not know if they had ever been tested for HIV or the results of any previous HIV test.⁴ Thus, estimating the prevalence of HIV among transgender persons may benefit from alternative methods as opposed to survey study questionnaires and meta-analyses with significant heterogeneity.

We thus sought to estimate the prevalence of HIV among transgender persons in clinical settings using an all-payer electronic health record (EHR) database, which to our knowledge is the first study to use these methods.

Materials and Methods

Data source

We utilized the cloud-based Explorys, Inc. (Cleveland, OH) database. Extensive reporting on this database, including the full methodology and technical features, has been described elsewhere.^{9,10} The data in Explorys are collected from health records, laboratory systems, and billing inquiries.¹⁰ Currently, ~60 million unique patient records from over 300 hospitals associated with 26 U.S. health care systems across all 50 states feed data from their respective EHRs to Explorys once every 24 h.

¹Department of Emergency Medicine, The Johns Hopkins School of Medicine, Baltimore, Maryland, USA.

²Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, Washington, USA.

³Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio, USA.

⁴Division of Population Health, Department of Emergency Medicine, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.

⁵Department of Internal Medicine, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.

*Address correspondence to: Jonathon W. Wanta, MD, Department of Psychiatry and Behavioral Sciences, University of Washington, 1514 Bellevue Avenue No. 606, Seattle, WA 98122, USA. E-mail: jwanta@uw.edu

Information from distinct EHRs is mapped into a single set of unified medical language system ontologies to standardize, normalize, and aggregate the data.⁹ More specifically, diagnoses and procedures for all patient records are mapped into Systematized Nomenclature of Medical Clinic Terms for clinical term (SNOMED-CT) hierarchies. SNOMED-CT collapses diagnostic codes from the international classification of diseases (ICD) into clinically meaningful, standardized categories using “umbrella” terms, while also documenting specific diagnoses, which allows researchers to utilize the web application’s PopEx system to search for disease, procedures, and findings at the epidemiological level of a de-identified, aggregated patient cohort. SNOMED-CT diagnoses can be mapped back to ICD codes using the U.S. National Library of Medicine’s Interactive Map-Assisted Generation of ICD Codes algorithm.

The Explorys database is compliant with both the Health Insurance Portability and Accountability Act (HIPAA) and the Health Information Technology for Economic and Clinical Health (HITECH) Act. As a HIPAA and HITECH compliant platform, information related to specific hospital systems in the Explorys database is not available to researchers. Finally, Explorys has been validated across numerous fields, including dermatology,¹¹ endocrinology,^{12,13} neurology,¹⁴ gynecology,¹⁵ gastroenterology,¹⁰ orthopedics,¹⁶ surgery,¹⁷ and hematology.⁹ Use of Explorys has been deemed exempt from Institutional Review Board approval by University Hospitals Cleveland Medical Center.

Cohort selection and definitions

We performed a retrospective analysis of the Explorys database for information collected between 1999 to April 2018. In this database, we selected all patients without missing demographic information. From this cohort, we identified an aggregated cohort of unique patients with a SNOMED-CT diagnosis of “transgender” at any time during the inclusion period, corresponding to previously published ICD-9 and ICD-10 classifications used to identify transgender patients in administrative claims databases (Supplementary Table S1).^{18–21} For the primary outcome of a diagnosis of HIV infection, we used the umbrella term “human immunodeficiency virus infection” to identify the prevalence of HIV, as previously described in a recent study.²² Other outcomes used diagnostic terms that correspond to their SNOMED-CT umbrella terms, such as “syphilis infection” and the specific opportunistic infec-

tions identified in Table 2. We compared these data to a non-transgender cohort that included all patients who had no transgender diagnosis during the study period and who had complete demographic information.

Statistical analysis

Demographic data are presented as numbers and percentages. Chi-squared tests and Fisher’s exact test were used to compare differences between groups. Given that Explorys rounds the number of patients to the nearest 10 for additional data protection, analyses were not conducted on outcomes that reported <10 patients as the data provided in Explorys is presented as “<10.” Statistical significance was set to $p < 0.05$. All analyses were performed using IBM SPSS Statistics, version 25 (IBM).

Results

We identified 53,449,400 patients without missing demographic data, of which 10,160 (0.019%) were transgender based on the aforementioned SNOMED search criteria. Table 1 lists baseline characteristics of transgender and non-transgender patients in the Explorys

Table 1. Characteristics of Patients in the Explorys Database

	Transgender cohort ^a	Non-transgender population ^a
Characteristics	N = 10,160	N = 53,449,400
Sex		
Male	4740 (46.6)	24,259,090 (45)
Female	5420 (53.3)	28,987,100 (54)
Age, years (%)		
0–14	190 (1.9)	6,405,720 (12.0)
15–29	4490 (44.1)	9,192,020 (17.2)
30–39	2210 (21.7)	7,703,400 (14.4)
40–49	1200 (11.8)	7,149,080 (13.4)
50–59	970 (9.5)	7,506,600 (14.04)
60–64	490 (4.8)	3,621,180 (6.77)
> 65	670 (6.6)	11,868,520 (22.2)
Median age, IQR	35–39 (25–29, 54–59)	40–44 (25–29, 60–64)
Race/ethnicity, n (%)		
Caucasian	6660 (65.5)	30,217,090 (56.53)
African American	1140 (11.2)	5,663,280 (10.60)
Hispanic/Latino	430 (4.2)	886,110 (1.66)
Asian	130 (1.2)	977,410 (1.83)
Other ^b	1800 (17.7)	11,991,870 (22.46)
Insurance type, n (%)		
Private	5520 (54.3)	20,879,650 (39.06)
Medicare	1030 (10.1)	5,965,830 (11.16)
Medicaid	2180 (21.4)	4,510,230 (8.44)
Self-pay	1380 (13.5)	7,180,500 (13.43)

^aExplorys reports data to the nearest 10. For this reason, percentages have been rounded and may not total 100.

^bIncludes Asian, Pacific Islander, Native American, Alaskan Native, Latin American, Native Hawaiian, and unknown.
IQR, interquartile range.

Table 2. Characteristics of Patients with History of HIV and Syphilis

Characteristics	Transgender cohort ^a	Non-transgender cohort ^a	p*
HIV demographics, n (%)	400 (3.9) ^b	170,870 (0.32) ^b	< 0.0001
Sex			
Male	280 (70)	102,290 (60)	< 0.0001
Female	120 (30)	68,380 (40)	
Race, n (%)			
African American	240 (60)	36,920 (22)	< 0.0001
Caucasian	90 (23)	102,670 (60)	
Other	20 (5)	18,630 (11)	
Unknown	30 (8)	17,880 (10)	
Insurance status, n (%)			
Medicaid	210 (53)	56,410 (33)	< 0.0001
Private	130 (33)	75,030 (44)	
Medicare	70 (18)	22,780 (13)	
Self-pay	40 (10)	17,960 (11)	
Syphilis demographics, n (%)	110 (1.1) ^b	35,340 (0.07) ^b	< 0.0001
Male	80 (73)	19,530 (55)	0.0002
Female	30 (27)	15,810 (44)	

*p-Values are from global χ^2 tests.

^aExplorys reports data to the nearest 10. For this reason, percentages have been rounded and may not total 100.

^bPercent of total population is noted in the parentheses. Total population for transgender patients is 10,160. Total population for the non-transgender cohort is 53,449,400.

database. Transgender patients were primarily female (53.3%), Caucasian (65.5%), 35–39 years of age (interquartile range: 25–29, 54–59), and with private insurance (54.3%). Table 2 lists baseline characteristics of people living with HIV (PLWH) in the Explorys database. The prevalence of HIV infection was significantly higher in the transgender cohort ($n=400$) compared to the non-transgender cohort ($n=170,870$; 3.9% vs. 0.32%, $p<0.0001$). Demographic factors associated with HIV infection included male sex as classified in the EHR ($p<0.0001$), African American race ($p<0.0001$), and Medicaid insurance status ($p<0.0001$).

Table 3. Opportunistic Infections and Immunization History Among Transgender and Non-Transgender Patients Living with HIV

	Transgender N = 400	Non-transgender N = 170,870	p***
Opportunistic infections, n (%)			< 0.0001
Bacterial pneumonia	100 (25)	3740 (2.2)	< 0.0001
Human papilloma virus	90 (23)	9610 (5.6)	< 0.0001
Candidiasis			
Oral	60 (15)	8870 (5.2)	< 0.0001
Esophageal	20 (5)	2440 (1.4)	< 0.0001
Tuberculosis	30 (8)	19,670 (12)	0.012
Pneumocystis pneumonia	20 (5)	1190 (0.70)	0.53

*p-Values are from global χ^2 tests.

**p-Values < 0.05 were considered statistically significant.

Similarly, the prevalence of opportunistic infections was higher in transgender PLWH compared to the non-transgender cohort living with HIV, except for pneumocystis pneumonia ($p=0.53$; Table 3).

Discussion

To our knowledge, this is the first study to estimate the prevalence of HIV among transgender persons in a clinical setting using EHR data from an all-payer database. We identified 3.4% of transgender patients living with HIV, while previous survey studies have observed prevalence ranging from 1.4% to 14% in survey studies and meta-analyses of case series, respectively.^{4,5,23} We chose to estimate prevalence of HIV in transgender patients using EHR data in an attempt to mitigate some of the limitations associated with survey studies. The data captured in survey studies regarding HIV status most often provide the answer choices “Yes,” “No,” or “I don’t know.”^{4,5} However, there are few reasons to question the prevalence of HIV from these studies, including (1) an estimated 15% of patients living with HIV in the United States do not know their serostatus^{7,24}; (2) psychosocial factors and perceived importance of information affect memory of an individual’s medical history²⁵; (3) previous studies suggest inaccuracies are introduced when prevalence metrics rely on self-reported information^{25–28}; and finally, (4) numerous studies have documented the phenomenon of nonacceptance of HIV as a coping mechanisms in vulnerable patients.^{29–32} For these reasons, there is sufficient susceptibility to underestimate disease prevalence in survey studies, particularly in a patient population with suspected increased baseline prevalence for HIV.

Our data confirm recent reports that transgender persons, including transgender women of color, have a higher prevalence of HIV compared to non-transgender persons.^{3,5} The highly cited 2015 Transgender Survey estimates the prevalence of HIV among transgender persons to be ~1.4% among survey respondents compared to the 3.9% documented in this study. However, over 40% of the participants in that survey did not know the results of a previous HIV test.⁴ Furthermore, while a greater proportion of transgender women in clinical care are living with HIV compared to the non-transgender cohort in this study (6.85% vs. 0.32%), a recent meta-analysis estimates the prevalence of HIV among transgender women to be around 21% in the United States. The aforementioned

study, however, was limited by significant heterogeneity ($I^2 = 98.5\%$).⁶

While data are limited regarding the disease burden of opportunistic infections among this patient population, our study suggests that transgender patients living with HIV are more likely to have opportunistic infections compared to non-transgendered patients living with HIV. This increased burden of disease may reflect initial presentation as an AIDS-defining illness, poor adherence, or lack of access to antiretroviral therapy. Finally, we provide data that suggest an increased prevalence of syphilis infection in transgender persons, especially among those with a history of HIV, which has been noted in preliminary systematic reviews and randomized control trials of transgender persons on pre-exposure prophylaxis.^{33,34}

Use of EHR data may limit the interpretation of prevalence of HIV among transgender patients throughout the United States for a few reasons. To begin, not all hospitals systems report HIV diagnoses or HIV testing to Explorys (personal communicating with IBM). In addition, we are limited by potential inconsistencies in documenting transgender identity in the EHR, which has been described extensively elsewhere.^{2,35,36} Given that the use of Explorys is both HIPAA and HITECH compliant, we did not have access to individual patient charts to further explore either transgender or HIV documentation. Although it is possible that the Explorys database may not contain a representative sample of clinical settings where individuals seek care for HIV, the prevalence of PLWH in Explorys is 0.33%, which approximates the Centers for Disease Control and Prevention reported prevalence of 0.37% in the United States.³⁷ Nevertheless, information from patients who receive screening through non-hospital systems, such as county health departments, stand-alone sexually transmitted disease clinics, and Free Clinics, are not included in the Explorys database.³⁷ By addressing these limitations in the future, cloud-based EHR data could be used to frequently monitor the health needs of this minority patient population on a national level compared to primary reliance on survey studies that have significant limitations.

Despite the aforementioned limitations, this study of transgender patients in clinical care using a nationwide, all-payer EHR database provides evidence of a higher prevalence of HIV among transgender compared to non-transgender patients in the Explorys database.

Author Disclosure Statement:

No competing financial interests exist.

Funding Information

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Supplementary Material

Supplementary Table S1

References

1. Rosendale N, Goldman S, Ortiz GM, Haber LA. Acute clinical care for transgender patients: a review. *JAMA Intern Med.* 2018;178:1535–1543.
2. How Many Adults Identify as Transgender in the United States. Williams Institute. June 2016. <https://williamsinstitute.law.ucla.edu/research/how-many-adults-identify-as-transgender-in-the-united-states>. Accessed August 28, 2018.
3. Meerwijk EL, Sevelius JM. Transgender population size in the United States: a meta-regression of population-based probability samples. *Am J Public Health.* 2017;107:e1–e8.
4. National Center for Transgender Equality. The Report of the 2015 U.S. Transgender Survey. 2016. www.ustranssurvey.org. Accessed August 28, 2018.
5. Centers for Disease Control and Prevention. 2015 Behavioral Risk Factor Surveillance System Questionnaire. 2015. Available at www.cdc.gov/brfss/brfssprevalence. Accessed April 1, 2019.
6. Centers for Disease Control and Prevention. National Health Interview Survey: Survey Description. 2016. [ftp://ftp.cdc.gov/pub/Health_Statistics/NCHS/Dataset_Documentation/NHIS/2016/srvydesc.pdf](http://ftp.cdc.gov/pub/Health_Statistics/NCHS/Dataset_Documentation/NHIS/2016/srvydesc.pdf). Accessed August 28, 2018.
7. Centers for Disease Control and Prevention. HIV Surveillance Report, 2016, Vol. 28. 2017. www.cdc.gov/hiv/library/reports/hiv-surveillance.html. Accessed August 28, 2018.
8. Baral SD, Poteat T, Strömdahl S, et al. Worldwide burden of HIV in transgender women: a systematic review and meta-analysis. *Lancet Infect Dis.* 2013;13:214–222.
9. Kaelber DC, Foster W, Gilder J, et al. Patient characteristics associated with venous thromboembolic events: a cohort study using pooled electronic health record data. *J Am Med Inform Assoc.* 2012;19:965–972.
10. Maradey-Romero C, Prakash R, Lewis S, et al. The 2011–2014 prevalence of eosinophilic oesophagitis in the elderly amongst 10 million patients in the United States. *Aliment Pharm Ther.* 2015;41:1016–1022.
11. Garg A, Kirby JS, Lavian J, et al. Sex- and age-adjusted population analysis of prevalence estimates for *Hidradenitis suppurativa* in the United States. *JAMA Dermatol.* 2017;153:760–764.
12. Blonde L, Meneghini L, Peng XV, et al. Probability of achieving glycemic control with basal insulin in patients with type 2 diabetes in real-world practice in the USA. *Diabetes Ther.* 2018;9:1347–1358.
13. Gottlieb A, Yanover C, Cahan A, Goldschmidt Y. Estimating the effects of second-line therapy for type 2 diabetes mellitus: retrospective cohort study. *BMJ Open Diabetes Res Care.* 2017;5:e000435.
14. Mirsky MM, Marrie RA, Rae-Grant A. Antidepressant drug treatment in association with multiple sclerosis disease-modifying therapy. *Int J MS Care.* 2016;18:305–310.
15. Yurteri-Kaplan LA, Mete MM, St Clair C, Iglesias CB. Practice patterns of general gynecologic surgeons versus gynecologic subspecialists for concomitant apical suspension during vaginal hysterectomy for uterovaginal prolapse. *South Med J.* 2015;108:17–22.
16. Pfeifferle KJ, Gil KM, Fening SD, Dilisio MF. Validation study of a pooled electronic healthcare database: the effect of obesity on the revision rate of total knee arthroplasty. *Eur J Orthop Surg Traumatol.* 2014;24:1625–1628.

17. Shanmugam VK, Fernandez SJ, Evans KK, et al. Postoperative wound dehiscence: predictors and associations. *Wound Repair Regen*. 2015;23:184–190.
18. Downing J, Conron K, Herman JL, Blosnich JR. Transgender and cisgender US veterans have few health differences. *Health Affairs*. 2018;37:1160–1168.
19. Dragon CN, Guerino P, Ewald E, Laffan AM. Transgender medicare beneficiaries and chronic conditions: exploring fee-for-service claims data. *LGBT Health*. 2017;4:404–411.
20. Proctor K, Haffer SC, Ewald E, et al. Identifying the transgender population in the Medicare program. *Transgender Health*. 2016;1:250–265.
21. Progovac AM, Cook BL, Mullin BO, et al. Identifying gender minority patients' health and health care needs in administrative claims data. *Health Affairs*. 2018;37:413–420.
22. Al-Kindi SG, ElAmm C, Ginwalla M, et al. Heart failure in patients with human immunodeficiency virus infection: epidemiology and management disparities. *Int J Cardiol*. 2016;218:43–46.
23. Becasen JS, Denard CL, Mullins MM, et al. Estimating the prevalence of HIV and sexual behaviors among the US transgender population: a systematic review and meta-analysis, 2006–2017. *Am J Public Health*. 2018;109:e1–e8.
24. Centers for Disease Control and Prevention. Monitoring Selected National HIV Prevention and Care Objectives by Using HIV Surveillance Data—United States and 6 Dependent Areas, 2016. HIV Surveill Suppl Report. 2018;23:51.
25. Kessels RPC. Patients' memory for medical information. *J R Soc Med*. 2003;96:219–222.
26. Khakoo NM, Lindsell CJ, Hart KW, et al. Patient perception of whether an HIV test was provided during the emergency department encounter. *J Int Assoc Provid AIDS Care*. 2014;13:506–510.
27. Coughlin SS. Recall bias in epidemiologic studies. *J Clin Epidemiol*. 1990;43:87–91.
28. Althubaiti A. Information bias in health research: definition, pitfalls, and adjustment methods. *J Multidiscip Healthc*. 2016;9:211–217.
29. Moitra E, Herbert JD, Forman EM. Acceptance-based behavior therapy to promote HIV medication adherence. *AIDS Care*. 2011;23:1660–1667.
30. Kamen C, Taniguchi S, Student A, et al. The impact of denial on health-related quality of life in patients with HIV. *Qual Life Res*. 2012;21:1327–1336.
31. Dailey AF, Hoots BE, Hall HI, et al. Vital signs: human immunodeficiency virus testing and diagnosis delays—United States. *MMWR Morb Mortal Wkly Rep*. 2017;66:1300–1306.
32. Beer L, Fagan JL, Valverde E, Bertolli J, Never in Care Project. Health-related beliefs and decisions about accessing HIV medical care among HIV-infected persons who are not receiving care. *AIDS Patient Care STDs*. 2009;23:785–792.
33. Kitayama K, Segura ER, Lake JE, et al. Syphilis in the Americas: a protocol for a systematic review of syphilis prevalence and incidence in four high-risk groups, 1980–2016. *Syst. Rev*. 2017;6:195.
34. Solomon MM, Mayer KH, Glidden DV, et al. Syphilis predicts HIV incidence among men and transgender women who have sex with men in a preexposure prophylaxis trial. *Clin Infect Dis*. 2014;59:1020–1026.
35. Cahill SR, Baker K, Deutsch MB, et al. Inclusion of sexual orientation and gender identity in stage 3 meaningful use guidelines: a huge step forward for LGBT health. *LGBT Health*. 2016;3:100–102.
36. McCarthy S, Reisner SL, Nunn A, et al. The time is now: attention increases to transgender health in the United States but scientific knowledge gaps remain. *LGBT Health*. 2015;2:287–291.
37. Niforatos J, Wanta J, Durbak E, et al. Assessing the national prevalence of HIV screening in the United States using electronic health record data. *Cureus*. 2019;11:e5043.

Cite this article as: Niforatos JD, Wanta JW, Durbak E, Cavendish J, Yax JA (2020) Prevalence of human immunodeficiency virus and opportunistic infections among transgender patients in the clinical setting: An all-payer electronic health record database study, *Transgender Health* 5:3, 191–195, DOI: 10.1089/trgh.2019.0030.

Abbreviations Used

EHR = electronic health record
 HIPAA = Health Insurance Portability and Accountability Act
 HITECH = Health Information Technology for Economic and Clinical Health
 IQR = interquartile range
 PLWH = people living with HIV
 SNOMED-CT = Systematized Nomenclature of Medical Clinic Terms for clinical term